GlaxoSmithKline's Ultra-Long-Acting Antibody Drug Gains Additional Approval in China

Stock News04-03

On April 3, the National Medical Products Administration (NMPA) website indicated that a new indication for GlaxoSmithKline PLC's "Depemokimab" has been approved for market entry in China, for the treatment of chronic rhinosinusitis with nasal polyps. Depemokimab is a novel anti-interleukin-5 (IL-5) monoclonal antibody developed by GSK, characterized by an extended half-life, high binding affinity, and high potency. It is the world's first ultra-long-acting IL-5 biologic administered just twice a year. Depemokimab received its first global approval in the United States in December 2025 for the treatment of eosinophilic asthma. It was first introduced to the Chinese market in March 2026. This latest approval marks the second indication for Depemokimab in China. GSK possesses a robust and industry-leading respiratory product pipeline. The newly approved Depemokimab is the successor to the once-monthly IL-5 inhibitor "Mepolizumab" (marketed as Nucala®), a blockbuster drug that generated $2.651 billion in revenue in 2025, and is poised to become the next market leader.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164920664?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-03 15:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164920664","market":"other","top_or_hot":-1,"title":"GlaxoSmithKline's Ultra-Long-Acting Antibody Drug Gains Additional Approval in China","media":"Stock News","content":"<p>On April 3, the National Medical Products Administration (NMPA) website indicated that a new indication for GlaxoSmithKline PLC's \"Depemokimab\" has been approved for market entry in China, for the treatment of chronic rhinosinusitis with nasal polyps. Depemokimab is a novel anti-interleukin-5 (IL-5) monoclonal antibody developed by GSK, characterized by an extended half-life, high binding affinity, and high potency. It is the world's first ultra-long-acting IL-5 biologic administered just twice a year. Depemokimab received its first global approval in the United States in December 2025 for the treatment of eosinophilic asthma. It was first introduced to the Chinese market in March 2026. This latest approval marks the second indication for Depemokimab in China. GSK possesses a robust and industry-leading respiratory product pipeline. The newly approved Depemokimab is the successor to the once-monthly IL-5 inhibitor \"Mepolizumab\" (marketed as Nucala®), a blockbuster drug that generated $2.651 billion in revenue in 2025, and is poised to become the next market leader.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GlaxoSmithKline's Ultra-Long-Acting Antibody Drug Gains Additional Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxoSmithKline's Ultra-Long-Acting Antibody Drug Gains Additional Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-03 15:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On April 3, the National Medical Products Administration (NMPA) website indicated that a new indication for GlaxoSmithKline PLC's \"Depemokimab\" has been approved for market entry in China, for the treatment of chronic rhinosinusitis with nasal polyps. Depemokimab is a novel anti-interleukin-5 (IL-5) monoclonal antibody developed by GSK, characterized by an extended half-life, high binding affinity, and high potency. It is the world's first ultra-long-acting IL-5 biologic administered just twice a year. Depemokimab received its first global approval in the United States in December 2025 for the treatment of eosinophilic asthma. It was first introduced to the Chinese market in March 2026. This latest approval marks the second indication for Depemokimab in China. GSK possesses a robust and industry-leading respiratory product pipeline. The newly approved Depemokimab is the successor to the once-monthly IL-5 inhibitor \"Mepolizumab\" (marketed as Nucala®), a blockbuster drug that generated $2.651 billion in revenue in 2025, and is poised to become the next market leader.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1164920664","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164920664","pubTimestamp":1775202991,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On April 3, the National Medical Products Administration (NMPA) website indicated that a new indication for GlaxoSmithKline PLC's \"Depemokimab\" has been approved for market entry in China, for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","GSKH":"GSK plc ADRhedged","GSK":"葛兰素史克","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"葛兰素史克超长效抗体药物在中国获得额外批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":1,"GSK":1,"GSKH":1},"content_text":"On April 3, the National Medical Products Administration (NMPA) website indicated that a new indication for GlaxoSmithKline PLC's \"Depemokimab\" has been approved for market entry in China, for the treatment of chronic rhinosinusitis with nasal polyps. Depemokimab is a novel anti-interleukin-5 (IL-5) monoclonal antibody developed by GSK, characterized by an extended half-life, high binding affinity, and high potency. It is the world's first ultra-long-acting IL-5 biologic administered just twice a year. Depemokimab received its first global approval in the United States in December 2025 for the treatment of eosinophilic asthma. It was first introduced to the Chinese market in March 2026. This latest approval marks the second indication for Depemokimab in China. GSK possesses a robust and industry-leading respiratory product pipeline. The newly approved Depemokimab is the successor to the once-monthly IL-5 inhibitor \"Mepolizumab\" (marketed as Nucala®), a blockbuster drug that generated $2.651 billion in revenue in 2025, and is poised to become the next market leader.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164920664","isCrawlerRequest":true}